Alzheimer’s Disease (AD) remains one of the most devastating neurodegenerative conditions globally, affecting millions of individuals and placing an overwhelming burden on families and healthcare systems. Characterized by progressive cognitive decline, memory loss, and the accumulation of toxic amyloid-beta (Aβ) plaques and neurofibrillary tangles, AD has long lacked effective disease-modifying treatments. However, recent advancements in non-invasive brain stimulation techniques have shed light on a promising candidate: Repetitive Transcranial Magnetic Stimulation (rTMS). This safe, non-surgical approach is emerging as a potential game-changer, with preclinical and clinical research highlighting its ability to target key pathological mechanisms and improve cognitive function in AD. In this blog, we’ll explore the science behind rTMS, its therapeutic potential, and why it offers new hope for the future of AD care.

Understanding rTMS: How It Works for Alzheimer’s Disease

rTMS leverages electromagnetic induction to deliver painless, focused magnetic pulses to specific brain regions. These pulses penetrate the skull, generating small electric currents that modulate neuronal activity, synaptic plasticity, and brain network connectivity—all of which are disrupted in AD (Wang et al., 2021). Unlike pharmaceutical treatments that often have limited efficacy and side effects, rTMS acts directly on the brain’s physiology, targeting multiple pathways involved in AD progression:

• Enhancing Toxic Protein Clearance: A core hallmark of AD is the buildup of Aβ plaques, which impair neuronal function and trigger inflammation. Studies on 5xFAD mice (a widely used AD model) have shown that high-frequency rTMS (20 Hz) significantly increases the drainage efficiency of the brain’s glymphatic system and meningeal lymphatics—critical pathways for clearing Aβ and other waste products (Lin et al., 2021). This leads to a notable reduction in Aβ deposits in key brain regions like the prefrontal cortex and hippocampus, which are vital for memory and cognition.
• Restoring Cognitive Function: Cognitive decline in AD is closely linked to impaired long-term memory and synaptic dysfunction. In preclinical trials, rTMS treatment prevented the loss of long-term memory for novel objects and locations in 5xFAD mice, with improvements attributed to preserved neuronal activity (measured via elevated c-FOS expression) and reduced glial cell activation (Lin et al., 2021). Clinical studies echo these findings: a randomized controlled trial of mild-to-moderate AD patients found that rTMS (administered to the dorsolateral prefrontal cortex) led to significant cognitive improvements lasting up to two months post-treatment (Moussavi et al., 2024).
• Modulating Neurotransmitters and Neurotrophic Factors: AD disrupts the balance of key neurotransmitters (e.g., dopamine, acetylcholine) and reduces levels of neuroprotective factors like Brain-Derived Neurotrophic Factor (BDNF). rTMS addresses this by upregulating dopamine receptor 4 (DR4) expression and increasing BDNF levels in the hippocampus and cerebral cortex—changes that promote neuronal survival, synaptic plasticity, and cognitive recovery (Choung et al., 2021). High-frequency rTMS (20 Hz) has been shown to be particularly effective in driving these neuroprotective effects (Antonioni et al., 2025).

Key Factors Shaping rTMS Efficacy in AD

For rTMS to reach its full potential as an AD treatment, several critical parameters must be optimized—findings that emerge from decades of preclinical and clinical research:

• Frequency Matters: High-frequency rTMS (≥5 Hz) consistently outperforms low-frequency stimulation (≤1 Hz) in improving cognitive function and reducing Aβ deposits. Meta-analyses confirm that 20 Hz rTMS, in particular, enhances cortical excitability, brain metabolism, and blood flow—key drivers of therapeutic benefit (Wang et al., 2021). Intermittent Theta Burst Stimulation (iTBS), a specialized rTMS protocol that delivers pulses in short bursts, offers similar efficacy to conventional rTMS but with shorter treatment sessions (5–10 minutes vs. 20–30 minutes), improving patient adherence (Huang et al., 2021).
• Targeted Stimulation Sites: The choice of brain region for stimulation significantly impacts outcomes. The dorsolateral prefrontal cortex (DLPFC) is a well-established target, with rTMS leading to improvements in language, attention, and executive function (Cotelli et al., 2011). Stimulating the precuneus— a region critical for memory and default mode network function—has also shown promise, enhancing episodic memory and neural activity in prodromal AD (Koch et al., 2018). Emerging research suggests that multi-target stimulation (e.g., combining DLPFC and precuneus) may yield even better results by addressing the widespread network dysfunction in AD (Lin et al., 2019).
• Timing and Duration: Early intervention is key. rTMS administered to 4–5-month-old 5xFAD mice (an early pathological stage) effectively halted cognitive decline and Aβ accumulation, whereas delayed treatment may be less effective (Lin et al., 2021). Clinically, long-term treatment (e.g., 6 weeks of intensive stimulation followed by maintenance sessions) sustains cognitive improvements, with some studies showing benefits lasting up to 12 weeks (Li et al., 2021).

The Future of rTMS in Alzheimer’s Care: What’s Next?

While rTMS has shown immense promise, ongoing research aims to address current limitations and expand its clinical utility:

• Personalized Medicine: Brain network connectivity patterns, measured via functional MRI (fMRI), can predict how individual AD patients will respond to rTMS. A recent study found that baseline dynamic functional network connectivity (dFNC) accurately forecasts memory improvements post-treatment, enabling tailored stimulation protocols (Chen et al., 2023). Combining fMRI-guided targeting with AI algorithms could soon allow clinicians to optimize rTMS parameters (frequency, intensity, site) for each patient.
• Combination Therapies: rTMS may work synergistically with other treatments. Preclinical research suggests that pairing rTMS with cognitive training or neuroprotective drugs enhances synaptic plasticity and Aβ clearance more effectively than either intervention alone (Rabey et al., 2013). Clinical trials are now exploring combinations of rTMS and cholinesterase inhibitors (standard AD medications) to amplify cognitive benefits.
• Biomarker Development: Identifying reliable biomarkers for rTMS efficacy is critical for clinical translation. Studies suggest that the clearance rate of contrast tracers in cerebrospinal fluid (CSF) and changes in blood BDNF levels could serve as non-invasive indicators of treatment success (Lin et al., 2021; Velioglu et al., 2021). These biomarkers would allow clinicians to monitor progress and adjust treatment plans in real time.

Safety and Accessibility: Why rTMS Stands Out

A major advantage of rTMS is its excellent safety profile. Unlike invasive brain stimulation techniques (e.g., deep brain stimulation), rTMS has no risk of infection or surgical complications. Adverse effects are mild and transient, primarily including headaches, scalp discomfort, or temporary tinnitus—with a seizure risk of less than 1 in 1000 (Gonsalvez et al., 2017). As rTMS devices become more compact and cost-effective, home-based treatment is becoming a reality, expanding access for patients who cannot attend frequent clinic visits.

Conclusion: A New Era for Alzheimer’s Treatment

Alzheimer’s Disease has long been a therapeutic challenge, but rTMS offers a beacon of hope. Backed by robust preclinical evidence (Lin et al., 2021; Choung et al., 2021) and growing clinical support (Moussavi et al., 2024; Chen et al., 2023), this non-invasive technique targets the root causes of AD—from Aβ accumulation to synaptic dysfunction—while improving cognitive function and quality of life. As research advances in personalized targeting, combination therapies, and biomarker development, rTMS is poised to become a cornerstone of AD care, transforming the lives of millions affected by this devastating disease.

The future of AD treatment is no longer limited to symptom management—with rTMS, we are moving toward disease modification and hope for a world where cognitive decline is no longer inevitable.

References

1. Antonioni, A., Martorana, A., Santarnecchi, E., Hampel, H., & Koch, G. (2025). The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer’s disease. Alzheimer’s & Dementia, 21(6), e70337.
2. Chen, H., Li, M., Qin, Z., et al. (2023). Functional network connectivity patterns predicting the efficacy of repetitive transcranial magnetic stimulation in the spectrum of Alzheimer’s disease. European Radiology Experimental, 7(63).
3. Choung, J. S., Kim, J. M., Ko, M. H., Cho, D. S., & Kim, M. Y. (2021). Therapeutic efficacy of repetitive transcranial magnetic stimulation in an animal model of Alzheimer’s disease. Scientific Reports, 11(1), 437.
4. Gonsalvez, I., Baror, R., Fried, P., et al. (2017). Therapeutic noninvasive brain stimulation in Alzheimer’s disease. Current Alzheimer Research, 14(4), 362–376.
5. Koch, G., Bonnì, S., Pellicciari, M. C., et al. (2018). Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer’s disease. NeuroImage, 169, 302–311.
6. Lin, Y., Jin, J., Lv, R., et al. (2021). Repetitive transcranial magnetic stimulation increases the brain’s drainage efficiency in a mouse model of Alzheimer’s disease. Acta Neuropathologica Communications, 9(1), 102.
7. Moussavi, Z., Uehara, M., Rutherford, G., et al. (2024). Repetitive transcranial magnetic stimulation as a treatment for Alzheimer’s disease: A randomized placebo-controlled double-blind clinical trial. Neurotherapeutics, 21(3), e00331.
8. Rabey, J. M., Dobronevsky, E., Aichenbaum, S., et al. (2013). Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: A randomized, double-blind study. Journal of Neural Transmission, 120(5), 813–819.
9. Velioglu, H. A., Hanoglu, L., Bayraktaroglu, Z., et al. (2021). Left lateral parietal rTMS improves cognition and modulates resting brain connectivity in patients with Alzheimer’s disease: Possible role of BDNF and oxidative stress. Neurobiology of Learning and Memory, 180, 107410.
10. Wang, J., Huang, L., Wei, L., & Chen, W. (2021). Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer’s disease. Journal of Zhejiang University (Medical Sciences), 50(3), 383–389.